Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03688243




Registration number
NCT03688243
Ethics application status
Date submitted
25/09/2018
Date registered
28/09/2018
Date last updated
10/03/2022

Titles & IDs
Public title
Non Exudative AMD Imaged With SS-OCT
Scientific title
Non Exudative Age-Related Macular Degeneration Imaged With Swept Source Optical Coherence Tomography
Secondary ID [1] 0 0
BIRC-01 IMPACT
Universal Trial Number (UTN)
Trial acronym
BIRC-01
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dry Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Treatment: Devices - SS-OCT imaging

Cohort 1 'IMPACT Cohort' - Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years

Cohort 2 'SWAGGER Cohort' - Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years

Cohort 3 - Subjects with GA enrolled in another trial


Treatment: Devices: SS-OCT imaging
All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in Choroidal Perfusion Deficits at 1 year compared to Baseline
Timepoint [1] 0 0
1 year time point
Secondary outcome [1] 0 0
Pre-existing sub-clinical Macular Neovascularization (MNV)
Timepoint [1] 0 0
1 year and 2-year time points
Secondary outcome [2] 0 0
Automated Drusen Volume measurements
Timepoint [2] 0 0
1 year and 2-year time points
Secondary outcome [3] 0 0
Automated GA measurements
Timepoint [3] 0 0
1 year and 2-year time points
Secondary outcome [4] 0 0
Structural OCT markers and Genetic Markers
Timepoint [4] 0 0
1 year and 2-year time points

Eligibility
Key inclusion criteria
1. Aged 50 and over

2. Clinic diagnosis of non-exudative iAMD in at least one eye with a drusen volume in the
central 3 mm circle centered on the fovea of at least 0.02 mm3 in the absence of GA or
nGA as diagnosed with OCT en face imaging OR Clinical diagnosis of early or
early/intermediate stage AMD in one eye in the absence of nGA or GA and exudative AMD
in the other eye OR clinical diagnosis of GA or nGA secondary to AMD that is at least
the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7
disc areas (17 mm2) in at least one eye which has never been treated with anti-VEGF
agents

3. Willing and able to comply with clinic visits and study-related procedures

4. Provide signed informed consent
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A subject who meets any of the following criteria will be excluded from the study:

1. Below the age of 50

2. Subjects with exudative AMD in both eyes

3. Eyes with evidence of non-proliferative and proliferative diabetic retinopathy.

4. Presence of confounding ocular diagnosis such as myopia >6D, or other ocular
conditions that may cause retinal pigment epithelium atrophy or exudative MNV

5. Subjects unable to give informed consent.

6. Subjects who are unable to comply with imaging guidelines

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/01/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2023
Actual
Sample size
Target
Accrual to date
Final
225
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Melbourne University CERA - East Melbourne
Recruitment postcode(s) [1] 0 0
3002 - East Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
New York

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Boston Image Reading Center
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The investigators wish to better understand the role of the choriocapillaris (CC) in the
formation and progression of non-exudative in age related macular degeneration (armd) by
imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by
studying their inter-dependence to determine if the loss of the CC could prove useful as an
anatomic clinical trial endpoint in future drug trials.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03688243
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Nadia Waheed, MD
Address 0 0
Boston Image Reading Center/Tufts Medical Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03688243